Inflammatix
Inflammatix Raises $57M in Series E Financing
The company said that it will use the money to support regulatory filings and commercialization of its 30-minute TriVerity Acute Infection and Sepsis Test.
Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up
Immunexpress, Diasorin, Cytovale, and Ad Astra are among the firms that gained clearances or began commercialization of tests in 2023 that could help guide treatment decisions.
The firm said it has secured US Food and Drug Administration breakthrough device designation for its test to classify infections and stratify patients by severe disease risk.